Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMBD-001 with Cetuximab +/- Docetaxel in Advanced Squamous Cell Carcinomas
NCT05910827Phase 2Recruiting
- Sponsor
- Hummingbird Bioscience
- Start
- Feb 2024
- Primary completion
- Dec 2027
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Therapeutic Vaccines
- Countries
- 5
01
Overview
A Phase 2 trial of hmbd-001 in squamous cell carcinoma (SCC), squamous cell carcinoma of the lung (SCCL), head and neck squamous cell carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC), cervical squamous cell carcinoma (CSCC), sponsored by Hummingbird Bioscience. Started Feb 2024; status: recruiting.
02
Drugs
hmbd-001
03
Conditions
squamous cell carcinoma (SCC)squamous cell carcinoma of the lung (SCCL)head and neck squamous cell carcinoma (HNSCC)Esophageal Squamous Cell Carcinoma (ESCC)cervical squamous cell carcinoma (CSCC)
Beyond the preview
Go deeper on NCT05910827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05910827.